Carcinoma of Unknown Primary with EML4‐ALK Fusion Response to ALK Inhibitors

With the advent of next‐generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Zhao, Peng, Peng, Ling, Wu, Wei, Zheng, Yi, Jiang, Weiqin, Zhang, Hangyu, Tong, Zhou, Liu, Lulu, Ma, Ruobing, Wang, Liping, Yao, Ming, Wang, Kai, Fang, Weijia, Wu, Liming
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Precision Medicine Clinic: Molecular Tumor Board
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459257/
https://ncbi.nlm.nih.gov/pubmed/30679319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0439
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados